$0.02
34.29%
NYSE, Fri, Sep 27 2024
ISIN
US78472W1045
Symbol
SQZ
Sector
Industry

SQZ Biotechnologies Co Stock price

$0.02
-0.07 74.44% 1M
-0.02 50.54% 6M
+0.00 15.58% YTD
-0.06 73.19% 1Y
-157.68 99.99% 3Y
-132.48 99.98% 5Y
-132.48 99.98% 10Y
NYSE, Closing price Fri, Sep 27 2024
-0.01 34.29%
ISIN
US78472W1045
Symbol
SQZ
Sector
Industry

Key metrics

Market capitalization $1.03m
Enterprise Value $12.31m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.02
P/S ratio (TTM) P/S ratio 0.09
P/B ratio (TTM) P/B ratio 0.55
Revenue growth (TTM) Revenue growth -44.62%
Revenue (TTM) Revenue $12.12m
EBIT (operating result TTM) EBIT $-60.65m
Free Cash Flow (TTM) Free Cash Flow $-74.55m
Cash position $10.19m
EPS (TTM) EPS $-2.43
Short interest 3.03%
Show more

Is SQZ Biotechnologies Co a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

SQZ Biotechnologies Co Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast SQZ Biotechnologies Co:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast SQZ Biotechnologies Co:

Buy
100%

Financial data from SQZ Biotechnologies Co

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '23
+/-
%
12 12
45% 45%
100%
- Direct Costs 11 11
1% 1%
90%
1.20 1.20
89% 89%
10%
- Selling and Administrative Expenses 4.28 4.28
35% 35%
35%
- Research and Development Expense 47 47
35% 35%
385%
-50 -50
26% 26%
-410%
- Depreciation and Amortization 11 11
1% 1%
90%
EBIT (Operating Income) EBIT -61 -61
23% 23%
-500%
Net Profit -72 -72
8% 8%
-591%

In millions USD.

Don't miss a Thing! We will send you all news about SQZ Biotechnologies Co directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

SQZ Biotechnologies Co Stock News

Neutral
PRNewsWire
almost 2 years ago
NEW YORK , Dec. 7, 2022 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against SQZ Biotechnologies Company ("SQZ" or "the Company") (NYSE: SQZ). Investors who purchased SQZ securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/sqz.

Company Profile

SQZ Biotechnologies Co. is a clinical-stage biotechnology company, which engages in developing cell therapies for patients with cancer, infectious diseases, and other serious conditions. It operates through SQZ Cell Therapy Platform, which uses membrane disruption to deliver material into cells. The company was founded by Robert S. Langer Jr., Klavis F. Jensen, Agustin Lopez Marquez, and Armon Sharei in March 2013 and is headquartered in Watertown, MA.

Head office United States
CEO Howard Bernstein
Founded 2013
Website www.sqzbiotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today